Good Life Advisors LLC Takes Position in Sana Biotechnology, Inc. $SANA

Good Life Advisors LLC purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,800 shares of the company’s stock, valued at approximately $46,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in Sana Biotechnology by 673.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after acquiring an additional 9,501 shares during the last quarter. Hoey Investments Inc. bought a new position in shares of Sana Biotechnology during the second quarter worth about $33,000. WealthPlan Investment Management LLC acquired a new position in Sana Biotechnology in the second quarter worth about $48,000. Los Angeles Capital Management LLC acquired a new stake in Sana Biotechnology during the second quarter valued at approximately $63,000. Finally, Brooklyn Investment Group bought a new position in Sana Biotechnology during the 1st quarter worth approximately $44,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Stock Performance

Shares of SANA stock opened at $3.99 on Friday. Sana Biotechnology, Inc. has a 1 year low of $1.26 and a 1 year high of $7.30. The firm has a market capitalization of $1.06 billion, a PE ratio of -4.11 and a beta of 1.94. The stock has a fifty day moving average of $4.17 and a two-hundred day moving average of $3.43.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. Equities research analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SANA shares. HC Wainwright lowered their target price on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 7th. JMP Securities set a $8.00 price objective on shares of Sana Biotechnology in a research report on Thursday, October 30th. Wedbush lifted their target price on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Citizens Jmp upped their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a report on Thursday, October 30th. Finally, Wall Street Zen raised Sana Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.33.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.